An observational study in Dementias and Neurodegenerative Dementia, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 2 sites in Italy. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Dementia with a site in Italy — 37 open to participants now, 44 under way, 7 of them phase 3. Dementia · Italy.
Among the 92 studies in Dementia with a site in Italy, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 12 that started in 2023, is one of 26 observational ones, reaches primary completion later than 26 of the 43 other live ones, and was the 80th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →37 of the 92 studies in Dementia with a site in Italy are open now. Recruiting first, the newest first:
Giovanna Zamboni · Sites in Italy
Ages 40+
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Italy, United States, Canada and 6 more countries
Ages 55–90
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 45+
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 50–86
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 18 · Phase 3 25 · Phase 4 1
First in 2001; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 252 across 554 observational studies indexed under Dementia.
Median enrollment 280 across the 66 interventional studies, 283 across the 26 observational. Of the 39 that completed or were terminated, 12 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 92 have an industry lead sponsor. The 10 most frequent:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is the lead sponsor of 84 studies on the registry; 32 are open to participants now.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
12 of the studies in Dementia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07404410Giovanna ZamboniRobotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel) | 2026-11-30 |
| NCT07625241Istituto Superiore di SanitàCST+MST Intervention on People Living With Mild-to-moderate Dementia | 2026-12 |
| NCT07287410IRCCS Centro Neurolesi Bonino PulejoDementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms. | 2026-12-20 |
| NCT05794061Istituto Auxologico ItalianoAdvances in Neuropsychological Diagnostics | 2026-12-31 |
| NCT07928453Neuromed IRCCSCardiovascular And Dementia Risk in diabeTes: the Role of Nox2- Related Oxidative Stress. | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 92 studies in Dementia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to evaluate the role of cholesterol in the pathogenesis of neurodegenerative dementias. Hypercholesterolemia is a known risk factor for Alzheimer disease (AD), and oxysterols, the principal cholesterol metabolites, are involved in neuroinflammation, amyloid aggregation, and tau accumulation.
Oxysterols will be measured in different biological samples (post-mortem brain tissue, CSF, and plasma) from patients with different neurodegenerative dementias, including AD, frontotemporal dementia (FTD), and primary tauopathies. This approach will allow determination of whether their modifications correlate primarily with Aß deposition, tauopathy, or neuronal loss, with the goal of identifying correlations with disease severity and progression.
Since preliminary results suggest that the levels of most oxysterols in the brain significantly increase in parallel with the levels of the enzyme PCSK9, the investigators will explore the role of cholesterol metabolism and PCSK9 in AD and other dementias to evaluate whether cholesterol dysregulation represents a common alteration across these neurodegenerative disorders or is specific to AD
The project is a monocentric retrospective and prospective low-intervention clinical study. All samples collected will be sent for analysis to the Laboratory of General Pathology and Pathophysiology, Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Recruitment and follow-up of patients with neurodegenerative dementias
Retrospective study Samples (CSF and plasma) previously collected from patients at Neurology 5 - Neuropathology Unit over the years will be used. The study will include 40 AD patients, 40 FTD patients, and 20 age-matched non-demented controls. Clinical and MRI data will be retrospectively collected, as well as levels of markers of neurodegeneration (tau, Abeta42, and phospho-tau) in CSF.
Longitudinal study During the first 18 months of the project, 30 AD patients, 20 FTD patients, and 10 patients with primary tauopathies (PSP/CBD) will be recruited. A group of 20 age-matched healthy subjects will serve as controls. All patients and controls will undergo a comprehensive neurologic assessment, a neuropsychological evaluation, and a brain MRI with a standard protocol at baseline (T0) and after 1 year (T1). CSF collection will be performed at baseline in patients. DNA and plasma will be collected from controls and patients at baseline and follow-up. Measurements of BMI, total cholesterol, LDL and HDL cholesterol, and triglycerides will be performed at baseline and follow-up in all subjects. ApoE genotype will be analyzed for all subjects to determine E2, E3, and E4 polymorphisms. MRI will be performed on a 3T scanner, including volumetric T1, FLAIR, T2, DWI, and DTI sequences at baseline and follow-up.
We will use samples (CSF and plasma) already collected from patients from Unit 1 over years. We will include 40 AD, 40 FTD and 20 age-matched non demented controls. Clinical and MRI data will be retrospectively collected as well as the levels of markers of neurodegeneration (tau, Abeta42 and phospho-tau) on CSF.
Longitudinal study We will recruit 30 AD patients, 20 FTD patients and 10 patients with primary tauopathies (PSP/CBD) from out and inpatients of Neurology 5-Neuropathology Unit. A group of 20 age-matched subjects without neurological and/or psychiatric diseases will be enrolled as controls. The duration of enrolment will be 18 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient with Alzheimer's disease
Patient wirh Frontotemporal dementia
Patient with tauopathy
Controll subjects
Characterize differences in cholesterol precursors
To identify and characterize differences in cholesterol precursors and metabolites between patients with neurodegenerative dementias vs controls and between patients with different types of neurodegenerative dementia.
Time frame: 12 months
different brain areas
To identify and characterize different levels of cholesterol precursors and metabolites as well as lipidomics and metabolomics changes in different brain areas of the same patients categorized as involved or spared by the different types of pathological changes.
Time frame: 12 months
cerebral oxysterol changes in AD
To find out whether cerebral oxysterol changes in AD (see preliminary results) involve globally the brain suggesting a general derangement of cerebral cholesterol metabolism or selectively brain areas involved by specific primary (Abeta deposition, tauopathy) or secondary (astrogliosis, microglial activation, neuroinflammation) alterations
Time frame: 12 months
different cholesterol precursors in neurodegenerative diseases examined in CSF and plasma
To identify different levels of cholesterol precursors and metabolites as well as lipidomics and metabolomics changes at different stages of the different neurodegenerative diseases examined in CSF and plasma.
Time frame: 12 months
cortical atrophy
To ascertain whether correlations exist between cholesterol precursors and metabolites abnormalities, severity of the disease, cortical atrophy, glial and microglial reactive changes and neuroinflammation in neurodegenerative dementias.
Time frame: 12 months
PCSK9
To verify whether changes in the levels of PCSK9 and other cholesterol metabolism-related proteins are present in patients with the neurodegenerative dementias (brain tissue, CSF, and plasma).
Time frame: 12 months
PCSK9 in neurons
Levels of inflammatory markers and neurodegeneration-related proteins in neurons and astrocytes after treatment with PCSK9 in vitro.
Time frame: 12 months
potential neurotoxic action of PCSK9
Efficacy of the new nanoparticle (NPs) formulation carrying anti-PCSK9 antibody in reducing PCSK9-induced neurotoxicity in neuronal and astrocyte cultures in vitro.
Time frame: 12 months
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Apr 2027, 46 months after the start.
Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 46 months is below that.
Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta